Taikang Asset Management (Hong Kong) CO LTD Bei Gene, Ltd. Transaction History
Taikang Asset Management (Hong Kong) CO LTD
- $937 Million
- Q3 2024
A detailed history of Taikang Asset Management (Hong Kong) CO LTD transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Taikang Asset Management (Hong Kong) CO LTD holds 7,000 shares of BGNE stock, worth $1.29 Million. This represents 0.17% of its overall portfolio holdings.
Number of Shares
7,000
Previous 7,000
-0.0%
Holding current value
$1.29 Million
Previous $998,000
57.41%
% of portfolio
0.17%
Previous 0.16%
Shares
1 transactions
Others Institutions Holding BGNE
# of Institutions
252Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.95 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.19 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$956 Million26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$919 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$684 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $19.2B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...